ES2001996A6 - Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad. - Google Patents

Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.

Info

Publication number
ES2001996A6
ES2001996A6 ES8602206A ES8602206A ES2001996A6 ES 2001996 A6 ES2001996 A6 ES 2001996A6 ES 8602206 A ES8602206 A ES 8602206A ES 8602206 A ES8602206 A ES 8602206A ES 2001996 A6 ES2001996 A6 ES 2001996A6
Authority
ES
Spain
Prior art keywords
diseases
versus
well
systemic lupus
chronic graft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8602206A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES2001996A6 publication Critical patent/ES2001996A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR COMPOSICIONES FARMACEUTICAS CONTRA ENFERMEDADES CRONICAS DE TRANSPLANTE FRENTE A HOSPEDANTE Y CONTRA ENFERMEDADES DE AUTOINMUNIDAD, EN EL QUE SE MEZCLA UN COMPUESTO DE FORMULAS 1 Y/O 2 O UNA SAL DEL COMPUESTO DE FORMULA 2 CON UNA SUSTANCIA AUXILIAR FARMACEUTICAMENTE INOCUA, Y SE ELABORA LA MEZCLA OBTENIDA HASTA DARLE UNA FORMA GALENICA APROPIADA PARA ADMINISTRACION POR VIA ORAL, RECTAL O INYECTABLE, ESTANDO COMPRENDIDAS LAS CANTIDADES DEL COMPUESTO ACTIVO ENTRE 1 Y 300 MG CON RELACION AL PESO TOTAL DE LA CORRESPONDIENTE UNIDAD DE DOSIFICACION. LAS COMPOSICIONES OBTENIDAS SON ESPECIALMENTE UTILES COMO UNIDADES DE DOSIFICACION DE MEDICAMENTOS PARA TRATAR EL LUPUS ERYTHEMATODES SISTEMICO.
ES8602206A 1985-09-27 1986-09-26 Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad. Expired ES2001996A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853534440 DE3534440A1 (de) 1985-09-27 1985-09-27 Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes

Publications (1)

Publication Number Publication Date
ES2001996A6 true ES2001996A6 (es) 1988-07-01

Family

ID=6282084

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8602206A Expired ES2001996A6 (es) 1985-09-27 1986-09-26 Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.

Country Status (11)

Country Link
US (1) US4965276A (es)
EP (2) EP0559238B1 (es)
JP (3) JP2514190B2 (es)
AT (1) ATE122033T1 (es)
AU (1) AU588629B2 (es)
CA (1) CA1275251C (es)
DE (3) DE3534440A1 (es)
ES (1) ES2001996A6 (es)
IE (1) IE61232B1 (es)
IL (1) IL80149A (es)
ZA (1) ZA867347B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US4975462A (en) * 1988-07-29 1990-12-04 Bristol-Myers Company Antiarthritic α-arylcarbamoyl cyanoacetic acid derivatives
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5268389A (en) * 1989-10-16 1993-12-07 Uniroyal Chemical Company, Inc. Thiocarboxylate ester compounds compositions containing the same
US5108999A (en) * 1990-02-02 1992-04-28 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
EP0538783B1 (de) * 1991-10-23 1995-09-27 Hoechst Aktiengesellschaft N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
GB9300083D0 (en) 1993-01-05 1993-03-03 Roussel Lab Ltd Chemical compounds
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
DE59407412D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
DE59407414D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
TW314467B (es) * 1993-03-31 1997-09-01 Hoechst Ag
WO1994024095A1 (en) * 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
LT3589B (en) 1993-11-30 1995-12-27 Hoechst Ag Using of known combination for treatment of rejection reaction by transplantation of organs
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
KR100365064B1 (ko) * 1994-10-17 2003-04-11 훽스트파마슈티칼스앤드케미칼스가부시키가이샤 I형알레르기성질환의예방및치료제
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
DE19612131A1 (de) * 1996-03-27 1998-01-22 Hoechst Ag Feste Arzneistoffzubereitung, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl) -anilid
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US20050255071A1 (en) * 1998-12-10 2005-11-17 Aventis Pharma Deutschland Gmbh Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
EP1381356B1 (en) 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
MXPA05006890A (es) 2002-12-23 2006-04-07 4Sc Ag Compuestos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
US20120172427A1 (en) 2009-09-18 2012-07-05 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
UA108760C2 (uk) 2010-07-01 2015-06-10 Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
CN105395539A (zh) * 2014-08-21 2016-03-16 欣凯医药化工中间体（上海）有限公司 泰瑞米特钠在制备治疗自身免疫病药物中的应用
WO2017056104A1 (en) 2015-09-28 2017-04-06 Natco Pharma Limited Stable pharmaceutical compositions of teriflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
WO2019175396A1 (en) 2018-03-16 2019-09-19 Immunic Ag Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP3900717B1 (en) 2020-04-21 2024-11-20 Immunic AG Vidofludimus for use in the treatment or prevention of viral diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DK545976A (da) * 1975-12-11 1977-06-12 Hoechst Ag Cyaneddikesyreanilidderivater fremgangsmade til deres fremstilling og midler der indeholder disse forbindelser
DE2555789A1 (de) * 1975-12-11 1977-07-07 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
EP0043150A1 (en) * 1980-06-24 1982-01-06 Akzo N.V. Pharmaceutical 2,3 -bis-hydroxybenzyl butane derivatives
US4435407A (en) * 1982-01-07 1984-03-06 Ciba-Geigy Corporation Certain substituted β-oxo-α-carbamoylpyrrolepropionitriles
US4435387A (en) * 1982-10-25 1984-03-06 American Cyanamid Company Poly-cation salts of bis (or tris) 4-O-polyhexose-thio-arylene sulfate derivatives
DE3405727A1 (de) * 1984-02-17 1985-08-22 Hoechst Ag, 6230 Frankfurt Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP0559238B1 (de) 1995-05-03
AU6316786A (en) 1987-04-02
JPH07165694A (ja) 1995-06-27
AU588629B2 (en) 1989-09-21
IE862554L (en) 1987-03-27
IE61232B1 (en) 1994-10-19
ZA867347B (en) 1987-05-27
JPS6272614A (ja) 1987-04-03
JPH0729918B2 (ja) 1995-04-05
EP0217206A2 (de) 1987-04-08
EP0217206A3 (en) 1989-06-14
IL80149A (en) 1990-11-29
DE3534440A1 (de) 1987-04-02
US4965276A (en) 1990-10-23
DE3689252D1 (de) 1993-12-09
JP2607848B2 (ja) 1997-05-07
EP0217206B1 (de) 1993-11-03
EP0559238A1 (de) 1993-09-08
JP2514190B2 (ja) 1996-07-10
JPH05208908A (ja) 1993-08-20
DE3650315D1 (de) 1995-06-08
CA1275251C (en) 1990-10-16
ATE122033T1 (de) 1995-05-15

Similar Documents

Publication Publication Date Title
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
JO1502B1 (en) New pharmacy vehicles
AU580262B2 (en) Drug administration
IT8021789A0 (it) Regolatore impiantabile perl'infusione di sostanze medicinali.
IT8622683A0 (it) Dispositivo terapeutico per la somministrazione di medicamenti.
IT1155619B (it) Bendaggio per la somministrazione di medicamenti
IT8721668A0 (it) Insufflatore per la somministrazione di farmaci sottoforma di polvere predosata in opercoli.
IT8567263A0 (it) Dispositivo di erogazione per la somministrazione controllata di un agente benefico particolamente di un farmaco a ruminanti
IT8621358A0 (it) Composizione farmaceutica adattivita' analgesica.
AU2152688A (en) Dosage form comprising fast agent delivery followed by slow agent delivery
EG18379A (en) Novel pharmacological compounds
IT8322832A0 (it) Dispositivo per la somministrazione controllata di farmaci.
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
AU3683484A (en) The use of menthol to enhance transdermal drug delivery
AU5824786A (en) Nasal inserts for the administration of pharmaceuticals
IE860785L (en) Composition for delivery of orally administered drugs
IT8248666A0 (it) Procedimento per produrre i glicosa minoglicani dermatansolfato ed eparan-solfato sostanzialmente puri eloro impiego farmaceutico
IT8521322A0 (it) Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche.
AU575892B2 (en) Tounge shaped pharmaceutical unit
EP0190860A3 (en) 6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
GB2153687B (en) Drug administration sets having polybutadiene tubing
CA2130988A1 (en) Pharmaceutical Composition for Treatment of Sudden Deafness
JPS5758630A (en) Interferon inducer

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2006-09-26

PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20060927